Eloxx Pharmaceuticals, Inc.

Executive Summary

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for nonsense mutation-driven rare diseases and cancers. The company's lead platform utilizes proprietary ribosome readthrough technology to enable the production of full-length, functional proteins from mutated genes. Eloxx recently completed a $66 million public offering and uplisted to Nasdaq in June 2026, providing capital to advance its pipeline. The company's primary candidate, ELX-02, targets nonsense mutations in cystic fibrosis and has shown promise in early-stage trials. Eloxx is also exploring applications in other genetic disorders and oncology indications, aiming to address significant unmet medical needs. With a strong cash position and upcoming clinical milestones, Eloxx is poised to deliver transformative treatments for patients with nonsense mutation diseases.

Upcoming Catalysts (preview)

• Q4 2026Topline results from Phase 2 trial of ELX-02 in cystic fibrosis50% success
• Q1 2027FDA acceptance of IND for next-generation readthrough agent70% success
• Q3 2026Orphan Drug Designation for ELX-02 in a new rare disease indication80% success